229 related articles for article (PubMed ID: 28535104)
1. Measuring the Value of New Drugs: Validity and Reliability of 4 Value Assessment Frameworks in the Oncology Setting.
Bentley TGK; Cohen JT; Elkin EB; Huynh J; Mukherjea A; Neville TH; Mei M; Copher R; Knoth R; Popescu I; Lee J; Zambrano JM; Broder MS
J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S34-S48. PubMed ID: 28535104
[TBL] [Abstract][Full Text] [Related]
2. Validity and Reliability of Value Assessment Frameworks for New Cancer Drugs.
Bentley TGK; Cohen JT; Elkin EB; Huynh J; Mukherjea A; Neville TH; Mei M; Copher R; Knoth R; Popescu I; Lee J; Zambrano JM; Broder MS
Value Health; 2017 Feb; 20(2):200-205. PubMed ID: 28237195
[TBL] [Abstract][Full Text] [Related]
3. Value Frameworks for the Patient-Provider Interaction: A Comparison of the ASCO Value Framework Versus NCCN Evidence Blocks in Determining Value in Oncology.
Shah-Manek B; Galanto JS; Nguyen H; Ignoffo R
J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S13-S20. PubMed ID: 28535103
[TBL] [Abstract][Full Text] [Related]
4. Oncologists' Perceptions of Drug Affordability Using NCCN Evidence Blocks: Results from a National Survey.
Shah-Manek B; Wong W; Ravelo A; DiBonaventura M
J Manag Care Spec Pharm; 2018 Jun; 24(6):565-571. PubMed ID: 29451078
[TBL] [Abstract][Full Text] [Related]
5. Verifying the value of existing frameworks for formulary review at a large academic health system: assessing inter-rater reliability.
Karas BL; Picone MF; Werner S; Holsopple M
J Manag Care Spec Pharm; 2021 Apr; 27(4):488-496. PubMed ID: 33769852
[No Abstract] [Full Text] [Related]
6. Evaluating Oncology Value-Based Frameworks in the U.S. Marketplace and Challenges in Real-World Application: A Multiple Myeloma Test Case.
Djatche LM; Goble JA; Chun G; Varga S
J Manag Care Spec Pharm; 2018 Jan; 24(1):39-46. PubMed ID: 29290169
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the ASCO Value Framework for Anticancer Drugs at an Academic Medical Center.
Wilson L; Lin T; Wang L; Patel T; Tran D; Kim S; Dacey K; Yuen C; Kroon L; Brodowy B; Rodondi K
J Manag Care Spec Pharm; 2017 Feb; 23(2):163-169. PubMed ID: 28125363
[TBL] [Abstract][Full Text] [Related]
8. Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration.
Molto C; Hwang TJ; Borrell M; Andres M; Gich I; Barnadas A; Amir E; Kesselheim AS; Tibau A
Cancer; 2020 Oct; 126(19):4390-4399. PubMed ID: 32697362
[TBL] [Abstract][Full Text] [Related]
9. Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks.
Del Paggio JC; Sullivan R; Schrag D; Hopman WM; Azariah B; Pramesh CS; Tannock IF; Booth CM
Lancet Oncol; 2017 Jul; 18(7):887-894. PubMed ID: 28583794
[TBL] [Abstract][Full Text] [Related]
10. Do the American Society of Clinical Oncology Value Framework and the European Society of Medical Oncology Magnitude of Clinical Benefit Scale Measure the Same Construct of Clinical Benefit?
Cheng S; McDonald EJ; Cheung MC; Arciero VS; Qureshi M; Jiang D; Ezeife D; Sabharwal M; Chambers A; Han D; Leighl N; Sabarre KA; Chan KKW
J Clin Oncol; 2017 Aug; 35(24):2764-2771. PubMed ID: 28574778
[TBL] [Abstract][Full Text] [Related]
11. Value Frameworks: Adaptation of Korean Versions of Value Frameworks for Oncology.
Bae G; Bae S; Lee D; Han J; Koo DH; Kim DY; Kim HJ; Oh SY; Lee HY; Lee JH; Han HS; Ha H; Kang JH
Int J Environ Res Public Health; 2021 Mar; 18(6):. PubMed ID: 33803663
[TBL] [Abstract][Full Text] [Related]
12. Comparative Assessment of Clinical Benefit Using the ESMO-Magnitude of Clinical Benefit Scale Version 1.1 and the ASCO Value Framework Net Health Benefit Score.
Cherny NI; de Vries EGE; Dafni U; Garrett-Mayer E; McKernin SE; Piccart M; Latino NJ; Douillard JY; Schnipper LE; Somerfield MR; Bogaerts J; Karlis D; Zygoura P; Vervita K; Pentheroudakis G; Tabernero J; Zielinski C; Wollins DS; Schilsky RL
J Clin Oncol; 2019 Feb; 37(4):336-349. PubMed ID: 30707056
[TBL] [Abstract][Full Text] [Related]
13. The Importance of Economic Perspective and Quantitative Approaches in Oncology Value Frameworks of Drug Selection and Shared Decision Making.
Waldeck AR; Botteman MF; White RE; van Hout BA
J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S6-S12. PubMed ID: 28535105
[TBL] [Abstract][Full Text] [Related]
14. Reliability of Oncology Value Framework Outputs: Concordance Between Independent Research Groups.
Del Paggio JC; Cheng S; Booth CM; Cheung MC; Chan KKW
JNCI Cancer Spectr; 2018 Jul; 2(3):pky050. PubMed ID: 31360865
[TBL] [Abstract][Full Text] [Related]
15. Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis.
Vokinger KN; Hwang TJ; Grischott T; Reichert S; Tibau A; Rosemann T; Kesselheim AS
Lancet Oncol; 2020 May; 21(5):664-670. PubMed ID: 32359489
[TBL] [Abstract][Full Text] [Related]
16. Value assessment in oncology drugs: funding of drugs for metastatic breast cancer in Canada.
Lemieux J; Audet S
Curr Oncol; 2018 Jun; 25(Suppl 1):S161-S170. PubMed ID: 29910659
[TBL] [Abstract][Full Text] [Related]
17. Why Value Framework Assessments Arrive at Different Conclusions: A Multiple Myeloma Case Study.
Westrich K; Buelt L; Dubois RW
J Manag Care Spec Pharm; 2017 Jun; 23(6-a Suppl):S28-S33. PubMed ID: 28535102
[TBL] [Abstract][Full Text] [Related]
18. Clinical benefit of cancer drugs approved in Switzerland 2010-2019.
Adam R; Tibau A; Molto Valiente C; Šeruga B; Ocaña A; Amir E; Templeton AJ
PLoS One; 2022; 17(6):e0268545. PubMed ID: 35687539
[TBL] [Abstract][Full Text] [Related]
19. Payer Perspectives on Patient-Reported Outcomes in Health Care Decision Making: Oncology Examples.
Brogan AP; DeMuro C; Barrett AM; D'Alessio D; Bal V; Hogue SL
J Manag Care Spec Pharm; 2017 Feb; 23(2):125-134. PubMed ID: 28125369
[TBL] [Abstract][Full Text] [Related]
20. Exploration of the ASCO and ESMO Value Frameworks for Antineoplastic Drugs.
Becker DJ; Lin D; Lee S; Levy BP; Makarov DV; Gold HT; Sherman S
J Oncol Pract; 2017 Jul; 13(7):e653-e665. PubMed ID: 28493760
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]